Tapewire

Nasdaq · USD

BCTX

BriaCell Therapeutics Corp.

Export transactions ↓
Tapewire entity
7454
SEC CIK
0001610820
Parsed reports
14

Last 12 months

Inside the activity.

0 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
May 14, 2024 Filed May 20, 2024 16:00 UTC
Lustig MarcDirector · 10% owner
PurchaseCommon Stock Warrants · Derivative 902,935 Not disclosed Strike: $2.11 Not disclosed
Disclosure

SEC source: 0001493152-24-020660 · ownership.xml · derivative · entry 2

Lustig Marc · CIK 0001940908 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By L5 Capital Inc.

Disclosed balance after: 902,935

Underlying: Common Stock · 902,935 shares

Expires not disclosed

F1 · price: The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.

F1 · derivative.exercise_date: The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.

F1 · derivative.expiration_date: The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.

Read SEC document
May 14, 2024 Filed May 20, 2024 16:00 UTC
Lustig MarcDirector · 10% owner
PurchaseCommon Shares 902,935 $2.22 $2,000,001.03
Disclosure

SEC source: 0001493152-24-020660 · ownership.xml · nonDerivative · entry 1

Lustig Marc · CIK 0001940908 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By L5 Capital Inc.

Disclosed balance after: 2,542,935

F1 · shares: The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer.

Read SEC document
December 28, 2022 Filed Dec 28, 2022 21:38 UTC
Bondarenko JamiesonDirector · Chairman
PurchaseCommon Shares 28,000 $4.58 $128,240.00
Disclosure

SEC source: 0001493152-22-036669 · ownership.xml · nonDerivative · entry 1

Bondarenko Jamieson · CIK 0001942516 · Director · Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 169,856

Read SEC document
December 23, 2022 Filed Dec 28, 2022 20:22 UTC
Williams William V.Director · President, CEO
PurchaseWarrant · Derivative 2,530 $1.94 Strike: $5.31 $4,908.20
Disclosure

SEC source: 0001493152-22-036643 · ownership.xml · derivative · entry 1

Williams William V. · CIK 0001939302 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,802

Underlying: Common Shares · 2,530 shares

Expires 2026-02-25

F1 · price: The price reported in Column 8 is a weighted average price. These Warrants were purchased in multiple transactions at prices ranging from $1.97 to $2.00 per Warrant, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Warrants purchased at each separate price within the ranges set forth herein.

Read SEC document
December 20, 2022 Filed Dec 21, 2022 02:02 UTC PurchaseCommon Shares 22,000 $5.35 $117,700.00
Disclosure

SEC source: 0001493152-22-036060 · ownership.xml · nonDerivative · entry 1

Bondarenko Jamieson · CIK 0001942516 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,856

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.